Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review

被引:4
|
作者
Ekwunife O.I. [1 ,2 ]
Grote A.G. [3 ]
Mosch C. [4 ]
O'Mahony J.F. [5 ]
Lhachimi S.K. [1 ,6 ]
机构
[1] Leibniz Institute for Prevention Research and Epidemiology-BIPS, Cooperative Research Group for Evidence-Based Public Health, Department of Prevention and Evaluation, Bremen
[2] Nnamdi Azikiwe University, Department of Clinical Pharmacy and Pharmacy Management, Awka
[3] Institute for Quality and Efficiency in Health Care (IQWiG), Cologne
[4] Institute for Research in Operative Medicine (IFOM), Universität Witten/Herdecke, Witten
[5] School of Medicine, Trinity College Dublin, Department of Health Policy and Management, Dublin
[6] Institute for Public Health and Nursing Research-IPP, Health Sciences Bremen, University of Bremen, Bremen
关键词
Cost-effectiveness analysis; Low- and middle-income countries; Mass vaccination; Papillomavirus vaccines; Uterine cervical neoplasm;
D O I
10.1186/s13643-015-0057-8
中图分类号
学科分类号
摘要
Background: Cervical cancer poses a huge health burden, both to developed and developing nations, making prevention and control strategies necessary. However, the challenges of designing and implementing prevention strategies differ for low- and middle-income countries (LMICs) as compared to countries with fully developed health care systems. Moreover, for many LMICs, much of the data needed for decision analytic modelling, such as prevalence, will most likely only be partly available or measured with much larger uncertainty. Lastly, imperfect implementation of human papillomavirus (HPV) vaccination may influence the effectiveness of cervical cancer prevention in unpredictable ways. This systematic review aims to assess how decision analytic modelling studies of HPV cost-effectiveness in LMICs accounted for the particular challenges faced in such countries. Specifically, the study will assess the following: (1) whether the existing literature on cost-effectiveness modelling of HPV vaccines acknowledges the distinct challenges of LMICs, (2) how these challenges were accommodated in the models, (3) whether certain parameters systemically exhibited large degrees of uncertainty due to lack of data and how influential were these parameters on model-based recommendations, and (4) whether the choice of modelling herd immunity influences model-based recommendations, especially when coverage of a HPV vaccination program is not optimal. Methods: We will conduct a systematic review to identify suitable studies from MEDLINE (via PubMed), EMBASE, NHS Economic Evaluation Database (NHS EED), EconLit, Web of Science, and CEA Registry. Searches will be conducted for studies of interest published since 2006. The searches will be supplemented by hand searching of the most relevant papers found in the search. Studies will be critically appraised using Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement checklist. We will undertake a descriptive, narrative, and interpretative synthesis of data to address the study objectives. Discussion: The proposed systematic review will assess how the cost-effectiveness studies of HPV vaccines accounted for the distinct challenges of LMICs. The gaps identified will expose areas for additional research as well as challenges that need to be accounted for in future modelling studies. Systematic review registration: PROSPERO CRD42015017870 . © 2015 Ekwunife et al.; licensee BioMed Central.
引用
收藏
相关论文
共 50 条
  • [41] Financing and cost-effectiveness of emergency medical services in low- and middle-income countries
    Delaney, Peter G.
    Offorjebe, Agatha
    Arudo, John
    SURGERY, 2024, 176 (04) : 1302 - 1304
  • [42] Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022
    Gharpure, Radhika
    Chard, Anna N.
    Escobar, Maria Cabrera
    Zhou, Weigong
    Valleau, Molly M.
    Yau, Tat S.
    Bresee, Joseph S.
    Azziz-Baumgartner, Eduardo
    Pallas, Sarah W.
    Lafond, Kathryn E.
    PLOS MEDICINE, 2024, 21 (01)
  • [43] Cost-effectiveness of a decentralized care model for managing multi-drug-resistant tuberculosis in low- and middle-income countries: a systematic review protocol
    Mahapatra, Biswajit
    Bhattacharya, Paramita
    Karuveettil, Vineetha
    John, Denny
    Khatoon, Sajda
    Mukherjee, Nirmalya
    Jankiram, Chandrashekar
    JBI EVIDENCE SYNTHESIS, 2024, 22 (01) : 97 - 105
  • [44] Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
    Afschin Gandjour
    PharmacoEconomics, 2014, 32 : 1245 - 1246
  • [45] Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low- and lower middle-income countries
    Anderson, John D.
    Bagamian, Karoun H.
    Muhib, Farzana
    Baral, Ranju
    Laytner, Lindsey A.
    Amaya, Mirna
    Wierzba, Thomas
    Rheingans, Richard
    VACCINE: X, 2019, 2
  • [46] Comment on: "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines"
    Gandjour, Afschin
    PHARMACOECONOMICS, 2014, 32 (12) : 1245 - 1246
  • [47] Challenges in Assessing Stroke Incidence in Low- and Middle-Income Countries
    Oliveira-Filho, Jamary
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (17):
  • [48] PROTOCOL: Language of instruction in schools in low- and middle-income countries: A systematic review
    Nakamura, Pooja
    Leyew, Zelealem
    Molotsky, Adria
    Ranjit, Varsha
    Kamto, Kevin
    CAMPBELL SYSTEMATIC REVIEWS, 2023, 19 (02)
  • [49] Assessing the quality of antenatal corticosteroids in low- and middle-income countries: A systematic review
    Mosoro, Euodia
    Wilson, Alyce N.
    Homer, Caroline S. E.
    Vogel, Joshua P.
    PLOS ONE, 2020, 15 (12):
  • [50] The cost-effectiveness of hypertension management in low-income and middle-income countries: a review
    Kostova, Deliana
    Spencer, Garrison
    Moran, Andrew E.
    Cobb, Laura K.
    Husain, Muhammad Jami
    Datta, Biplab Kumar
    Matsushita, Kunihiro
    Nugent, Rachel
    BMJ GLOBAL HEALTH, 2020, 5 (09):